PTC Therapeutics (PTCT) announced that it has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher for $150M upon the closing of the transaction. PTC was granted the PRV on November 13 along with the U.S. FDA approval of KEBILIDI for the treatment of children and adults with AADC deficiency, including the full spectrum of disease severity. The transaction is subject to customary closing conditions, including expiration of the applicable waiting period under the Hart-Scott Rodino Antitrust Improvements Act.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics: Phase 2 CardinALS study did not meet its primary endpoint
- PTC Therapeutics price target raised to $62 from $51 at JPMorgan
- PTC Therapeutics price target raised to $45 from $43 at Barclays
- PTC Therapeutics’ AADC deficiency gene therapy granted FDA approval
- PTC Therapeutics price target raised to $43 from $31 at Barclays